David Sallman, MD, on Advantages of Allogeneic CAR T-Cell Therapy in AML

“Patients that have relapsed refractory acute myeloid leukemia (AML) have very limited options and often with survival measures in even weeks to months. Whereby CAR T has really brought forth a paradigm shift in the treatment of patients with hematologic malignancies, especially B cell malignancies, we have really not gotten there yet in the field of AML. But that is really where we're trying to go.”

Alemtuzumab plus fludarabine and cyclophosphamide lymphodepleting regimen led to improved lymphodepletion and significantly higher UCART123v1.2 cell expansion and persistence in the phase 1/2 AMELI-01 clinical trial (NCT04106076). Updated data from the trial were presented at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana, by David Sallman, MD, assistant member, department of malignant hematology, Moffitt Cancer Center.

CGTLive spoke with Sallman to learn more about the unmet needs in patients with AML and how the UCART123v1.2 chimeric antigen receptor (CAR) T-cell therapy's properties may offer advantages to this population, including how allogeneic therapies may be more suitable than autologous ones. He also discussed challenges with targeting CD123.

Click here to read more coverage of the 2022 ASH Meeting.

REFERENCE

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML). Presented atL 64th ASH Annual Meeting, December 10-12, New Orleans, Louisiana. Abstract #981